Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy,…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years. The company also made the…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase…
CAMBRIDGE, MA and RAHWAY, N.J., April 6, 2023 – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients…
RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2023. “Inspired by our commitment to bring bold science forward to address critical unmet patient needs, we…
The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced that Regional Cancer Care Associates (RCCA) entered into a strategic relationship with The Network effective April 1,…
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Reata Pharmaceuticals as the sole specialty pharmacy provider for SKYCLARYSTM (omaveloxolone), the first and only treatment for Friedreich’s ataxia (FA). SKYCLARYS was approved by the…
McKesson ideaShare in Las Vegas from June 22–25, 2023. McKesson ideaShare is the nation’s premier community pharmacy annual education and networking event, hosted by McKesson, Health Mart, and Health Mart Atlas. The event returns with double the clinical and business educational opportunities, new pharmacy…
Kalamazoo, Michigan, May 01, 2023 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) reported operating results for the first quarter of 2023: First Quarter Results First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions /…
First-Quarter 2023 Revenues of $18.3 Billion – Expected Decline in Comirnaty(1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues – First-Quarter 2023 Revenues from Comirnaty(1) and Paxlovid of $7.1 Billion – Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew…